FDA Approves Deflazocort (Emflaza®) To Treat Duchenne Muscular Dystrophy (DMD)

On February 9th, 2017 the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy [...]

February 15th, 2017|Blog, News, Pharmacy|

Mounting Problem of Opioid Diversion: Major Emerging Problem for Health Systems in US

The fight against the diversion of opioids and other controlled substances is heating up in the nation’s health systems, according to experts at a packed session at the 2016 annual [...]

January 17th, 2017|Blog, Pharmacy|

Direct Switching From TNF Rheumatoid Arthritis (RA) Drugs Shows Beneficial Effect in Non-Responsive Patients

Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated [...]

November 21st, 2016|Blog, Pharmacy|

American Society of Health-System Pharmacists (ASHP) Publishes the First Set of National Guidelines Regarding Controlled Substances Diversion Prevention Guidelines

On 10/28/2016 the American Society if Health-System Pharmacists (ASHP) announced the publishing of the first set of national guidelines designed to help healthcare organizations devise and implement strategies to prevent [...]

November 1st, 2016|Blog, Pharmacy|

FDA Warns About Amputation Risk With Canagliflozin (Invokana®)

The US Food and Drug Administration (FDA) has issued a new safety alert that the diabetes drug canagliflozin (Invokana, Invokamet, Janssen) has been associated with an approximately twofold risk for [...]

October 24th, 2016|Blog, Pharmacy|

Hospital Data Show Skyrocketing Drug Prices

On October 11th, 2016 it was reported that a new analysis of drug pricing data finds that inpatient hospital drug costs increased more than 38% per admission between 2013 and [...]

October 23rd, 2016|Blog, Pharmacy|